Jean S Campbell
Overview
Explore the profile of Jean S Campbell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
2657
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Finton K, Rupert P, Friend D, Dinca A, Lovelace E, Buerger M, et al.
Front Immunol
. 2023 May;
14:1170462.
PMID: 37207206
MHC class I "" molecules, coupling MHC heavy chain, β-microglobulin, and a specific peptide into a single polypeptide chain, are widely used in research. To more fully understand caveats associated...
2.
Andtbacka R, Wang Y, Pierce R, Campbell J, Yushak M, Milhem M, et al.
Cancer Res Commun
. 2023 Mar;
2(8):904-913.
PMID: 36923305
Purpose: Mavorixafor is an oral, selective inhibitor of the CXCR4 chemokine receptor that modulates immune cell trafficking. A biomarker-driven phase Ib study (NCT02823405) was conducted in 16 patients with melanoma...
3.
Church C, Pulliam T, Longino N, Park S, Smythe K, Makarov V, et al.
J Immunother Cancer
. 2022 Oct;
10(9).
PMID: 36252564
Background: Merkel cell carcinoma (MCC) often responds to PD-1 pathway blockade, regardless of tumor-viral status (~80% of cases driven by the Merkel cell polyomavirus (MCPyV)). Prior studies have characterized tumor-specific...
4.
Campbell J, Pai S
Cancer J
. 2022 Sep;
28(5):407-415.
PMID: 36165730
Despite the availability of prophylactic human papillomavirus (HPV) vaccines, there is a growing incidence of HPV-associated head and neck squamous cell carcinomas (HPV-HNSCC) worldwide. The viral etiology of HPV-HNSCC provides...
5.
Voillet V, Berger T, McKenna K, Paulson K, Hong Tan W, Smythe K, et al.
J Immunol
. 2022 Jul;
209(3):606-620.
PMID: 35817516
Despite recent therapeutic progress, advanced melanoma remains lethal for many patients. The composition of the immune tumor microenvironment (TME) has decisive impacts on therapy response and disease outcome, and high-dimensional...
6.
Schroeder B, Zhang Y, Smythe K, Desai P, Thomas A, Viveiros P, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267598
Patients with metastatic soft tissue sarcoma (STS) have a poor prognosis and few available systemic treatment options. Trabectedin is currently being investigated as a potential adjunct to immunotherapy as it...
7.
Goff P, Riolobos L, LaFleur B, Spraker M, Seo Y, Smythe K, et al.
Clin Cancer Res
. 2022 Feb;
28(8):1701-1711.
PMID: 35115306
Purpose: To characterize changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy with the goal of informing neoadjuvant immunotherapy trial design. Experimental Design: Paired pre-...
8.
Schroeder B, LaFranzo N, LaFleur B, Gittelman R, Vignali M, Zhang S, et al.
J Immunother Cancer
. 2021 Sep;
9(8).
PMID: 34465597
Background: Dedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the observation of clinical responses to inhibitors, little...
9.
Wright J, Huang L, Weaver S, Archila L, McAfee M, Hirayama A, et al.
J Immunol Methods
. 2020 Dec;
492:112955.
PMID: 33383062
Identifying engineered T cells in situ is important to understand the location, persistence, and phenotype of these cells in patients after adoptive T cell therapy. While engineered cells are routinely...
10.
OBrien V, Koehne A, Dubrulle J, Rodriguez A, Leverich C, Kong V, et al.
Life Sci Alliance
. 2020 Dec;
4(2).
PMID: 33310760
More than 80% of gastric cancer is attributable to stomach infection with (). Gastric preneoplastic progression involves sequential tissue changes, including loss of parietal cells, metaplasia and dysplasia. In transgenic...